Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ALK Positive Non-small Cell Lung Cancer × lorlatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Non Small Cell Lung Cancer Metastatic 3 Lung Neoplasms 3 Recurrence 1 Neoplasms 1 Neoadjuvant Non-Small Cell Lung Cancer 1 Lymphoma, Large-Cell, Anaplastic 1 Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1 Advanced Non-Small Cell Lung Cancer 1 ALK Positive Non-small Cell Lung Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Guangdong Association of Clinical Trials

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡